These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
307 related items for PubMed ID: 3343727
1. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg LR. J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727 [Abstract] [Full Text] [Related]
2. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC. J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749 [Abstract] [Full Text] [Related]
3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N. Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654 [Abstract] [Full Text] [Related]
4. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosl G, Morse MJ, Sogani PC, Watson RC, Dershaw DD, Reuter V. J Urol; 1988 Mar 15; 139(3):470-4. PubMed ID: 3343728 [Abstract] [Full Text] [Related]
6. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer. Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C. Cancer Chemother Pharmacol; 1992 Mar 15; 30 Suppl():S72-6. PubMed ID: 1394823 [Abstract] [Full Text] [Related]
7. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity]. Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T. Nihon Hinyokika Gakkai Zasshi; 1991 Oct 15; 82(10):1627-36. PubMed ID: 1770701 [Abstract] [Full Text] [Related]
9. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer]. Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J. Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214 [Abstract] [Full Text] [Related]
10. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers. Ogawa T, Gotoh A, Takenaka A, Hara I, Gohji K, Arakawa S, Matsumoto O, Kamidono S. Cancer Chemother Pharmacol; 1992 Feb 15; 30 Suppl():S66-71. PubMed ID: 1394822 [Abstract] [Full Text] [Related]
11. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF. J Clin Oncol; 1997 Jun 15; 15(6):2449-55. PubMed ID: 9196161 [Abstract] [Full Text] [Related]
12. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer]. Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H. Hinyokika Kiyo; 2004 Oct 15; 50(10):667-71. PubMed ID: 15575216 [Abstract] [Full Text] [Related]
13. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Vlamis V, Higgins G, Herr H, Bajorin DF. Cancer; 1999 Mar 01; 85(5):1145-50. PubMed ID: 10091800 [Abstract] [Full Text] [Related]
15. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report. Lee MH, Chen MT, Chen KK, Lin AT, Lee YH, Lee LM, Chang YM, Chang LS, Liu JM, Hsieh RK. Cancer Chemother Pharmacol; 1992 Mar 01; 30 Suppl():S81-4. PubMed ID: 1394825 [Abstract] [Full Text] [Related]
17. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer. Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K. Cancer Chemother Pharmacol; 1994 Mar 01; 35 Suppl():S5-8. PubMed ID: 7527735 [Abstract] [Full Text] [Related]
18. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM. J Urol; 1993 Jul 01; 150(1):65-9. PubMed ID: 8510277 [Abstract] [Full Text] [Related]
19. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer]. Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O. Hinyokika Kiyo; 1988 Aug 01; 34(8):1371-5. PubMed ID: 3195405 [Abstract] [Full Text] [Related]
20. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]. Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A. Gan To Kagaku Ryoho; 1990 Sep 01; 17(9):1909-15. PubMed ID: 2393308 [Abstract] [Full Text] [Related] Page: [Next] [New Search]